Bio Pharma Dive

MAY 12, 2021

The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed.

Licensing 246

Licensing Licensing Drugs Development 246

Pharmaceutical Technology

JULY 7, 2023

Shorla Oncology has signed a licensing agreement with an undisclosed drug UK firm for a chemotherapy drug, PIP-101.

Licensing 130

Licensing Licensing Drugs 130

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 23, 2024

The Central Drugs Standard Control Organisation (CDSCO) has requested all stakeholders in the medical devices sector to deposit the requisite fee for retention of license or registration certificate under the Medical Devices Rules (MDR), 2017, well before the stipulated timeline in order to avoid cancellation of the approvals.The drug regulator, in (..)

Licensing 148

Licensing Licensing Regulation Drugs 148

Pharmaceutical Technology

SEPTEMBER 7, 2023

IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).

Licensing 147

Licensing Licensing Drugs 147

Outsourcing Pharma

NOVEMBER 7, 2023

A breast cancer drug that has been used for many years to treat the disease, has been licensed today (November 7) as a preventative measure.

Licensing 111

Licensing Licensing Drugs Clinical Development 111

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 20, 2023

Empowering of the Central Drugs Standard Control Organisation (CDSCO) through centralisation of drug licensing may not be the path to improve the quality of drugs manufactured in the country both for domestic and international markets, says SME Pharma Industries Confederation (SPIC), the apex organisation of small and medium pharma industries in the (..)

Licensing 147

Licensing Licensing Drugs Manufacturing 147

Drug Discovery World

MAY 31, 2024

Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. The drug has a long history of use by traditional healers and may have the potential to be the first in a new class of plant-based antipsychotic compounds.

Licensing 59

Licensing Licensing Drugs Medicine 59

Pharmaceutical Technology

OCTOBER 5, 2023

Antibody-drug conjugates (ADCs) saw a 400% growth in total licensing agreement deal value from 2017 to 2022 and reached a peak of $16.6bn.

Licensing 130

Licensing Licensing Antibody Drugs 130

pharmaphorum

APRIL 2, 2024

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

Licensing 105

Licensing Licensing Antibody Drugs 105

Outsourcing Pharma

JULY 18, 2023

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

DNA 97

DNA Licensing Licensing Drugs 97

Bio Pharma Dive

FEBRUARY 1, 2024

The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.

Licensing 273

Licensing Licensing Production Drugs 273

pharmaphorum

JANUARY 25, 2024

Indian pharma Glenmark has licensed rights to subcutaneous PD-L1 inhibitor envafolimab from China’s Alphamab and 3D Medicines

Licensing 110

Licensing Licensing Medicine Drugs 110

Pharmaceutical Technology

JUNE 14, 2024

If exercised, the option would allow Takeda to license the TKI olverembatinib outside China, Hong Kong, Macau, Taiwan and Russia.

Licensing 258

Licensing Licensing Drugs 258

pharmaphorum

NOVEMBER 1, 2023

GSK licenses hepatitis B drug from J&J in $1bn deal Phil.Taylor Wed, 01/11/2023 - 10:25 Bookmark this

Licensing 110

Licensing Licensing Drugs 110

Pharma Mirror

APRIL 18, 2023

The license allows Sterling to manufacture antibody-drug conjugates (ADCs) for clinical use in its current Good Manufacturing Practices (cGMP) compliant manufacturing facility in Deeside, UK.

Licensing 130

Licensing Licensing Manufacturing Antibody 130

Pharmaceutical Technology

NOVEMBER 20, 2023

Serina Therapeutics’ polymer aims to overcome certain limitations of the commonly used polyethylene glycol for drug delivery.

Drug Delivery 147

Drug Delivery Licensing Licensing Drugs 147

Fierce Pharma

OCTOBER 4, 2023

Colombian authorities say they plan to issue a compulsory license for ViiV Healthcare's dolutegravir, which goes by the name Tivicay on its own or as Dovato when combined with other therapeutics. The idea behind the compulsory license is to allow the Colombian government to purchase cheaper generic versions.

Licensing 118

Licensing Licensing Drugs 118

Bio Pharma Dive

JUNE 21, 2024

Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead. A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study.

Licensing 156

Licensing Licensing Development Antibody 156

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 7, 2024

The national drug regulator has withdrawn the powers delegated to the State and Union Territory (UT) Licensing Authorities to issue No Objection Certificates (NOCs) for manufacture of unapproved, banned or new drugs solely for export purpose, asking the industry to file fresh applications with the central authority online from May 15.

Drugs 171

Drugs Licensing Licensing Regulation 171

Bio Pharma Dive

APRIL 2, 2024

A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

Drugs 164

Drugs Licensing Licensing 164

Pharmaceutical Technology

JUNE 20, 2023

The investigational drug candidate vamorolone has a mode of action based on binding to the same receptor as glucocorticoids while changing its downstream activity. In the US and Europe, the drug has received orphan drug status to treat Duchenne muscular dystrophy (DMD).

Licensing 246

Licensing Licensing Medicine Drugs 246

Bio Pharma Dive

MARCH 28, 2024

Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

Licensing 280

Licensing Licensing Drugs 280

Bio Pharma Dive

JULY 25, 2022

The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.

RNA 246

RNA Licensing Licensing Drugs 246

BioPharma Reporter

MAY 20, 2024

CRISPR licensing company ERS Genomics and drug discovery firm IRBM have entered into a non-exclusive CRISPR/Cas9 license agreement.

Licensing 52

Licensing Licensing Genome Genomics 52

Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Denali is also expected to receive potential development and commercial milestone payments upon achieving certain milestones, along with royalties based on the future net sales of the drug.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Bio Pharma Dive

MAY 31, 2023

The medicine, licensed from biotech ImmuNext in 2017, is one of two later-stage MS drug prospects in the French drugmaker’s portfolio.

Licensing 265

Licensing Licensing Drugs Medicine 265

BioSpace

NOVEMBER 23, 2021

A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.

Licensing 109

Licensing Licensing Drugs 109

Bio Pharma Dive

JUNE 14, 2024

Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.

Licensing 148

Licensing Licensing Antibody Drugs 148

Pharmaceutical Technology

JANUARY 4, 2024

BridGene has entered into a strategic partnership and licensing deal with Galapagos for the discovery of drug candidates for oncology targets.

Drugs 147

Drugs Licensing Licensing 147

BioPharma Reporter

OCTOBER 31, 2023

The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.

Licensing 59

Licensing Licensing Drug Delivery Drugs 59

Pharma Mirror

OCTOBER 1, 2022

HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Simcere will retain all rights to develop and commercialise SIM0278 within Greater China.

Licensing 130

Licensing Licensing Protein Development 130

Bio Pharma Dive

JULY 12, 2022

Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment.

Licensing 269

Licensing Licensing Drugs Development 269

Pharmaceutical Technology

OCTOBER 13, 2023

MediLink will receive $70m upfront and will be eligible for up to $1bn in additional milestone-based payments from BioNTech.

Licensing 147

Licensing Licensing Antibody Drugs 147

Bio Pharma Dive

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Licensing 291

Licensing Licensing Regulation Research 291

pharmaphorum

JULY 1, 2024

billion strategic alliance with Eisai focusing on ADCs for cancer, returning rights to lead drug FZEC Bristol-Myers Squibb ends $3.1

Licensing 97

Licensing Licensing Drugs 97

Bio Pharma Dive

MAY 9, 2024

The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

Licensing 177

Licensing Licensing Medicine Drugs 177

Bio Pharma Dive

OCTOBER 17, 2022

Executives said the biotech could search for a new partner for the geographic atrophy drug if Merck decides not to license it under an existing deal.

Licensing 251

Licensing Licensing Drugs 251